Tagged with CGT

USA Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape. Kim examines the prevailing sentiment of the industry amidst a period of significant structural upheaval and regulatory whiplash. He offers…

Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…

Global Cell and gene therapies are redefining the boundaries of what is scientifically and operationally possible in healthcare, but bringing these innovations to patients at scale requires more than breakthrough science. In this conversation, Ralf Altenburger, Global Head of Cell & Gene Therapy at Roche, discusses how the company is navigating…

Switzerland Luc Henry, co-founder and CEO of Limula, speaks about the challenges and opportunities in the field of cell and gene therapy. A chemist by training, Henry’s path from molecular sciences to cancer immunology and ultimately to entrepreneurship reveals how interdisciplinary thinking can catalyse bold innovation. In this conversation, Henry explains…

Switzerland Daniel Palmacci, Head of Specialized Modalities at Lonza, combines entrepreneurial vision with deep technical expertise in advanced therapeutics manufacturing. With experience spanning chemical engineering, international operations, and biotechnology development across Europe, the Americas, and Asia, he has played a pivotal role in transforming laboratory discoveries into commercial treatments. In this…

Switzerland Combining scientific rigour with entrepreneurial instinct, Igor Fisch charts a new path for gene and cell therapy manufacturing at NewBiologix. Focused on addressing the inefficiencies of current production models, the company develops stable platforms designed to lower costs, enhance quality, and expand patient access. With roots in the pioneering success…

Global Dr Vivienne Marshall, senior director of the Center for Advanced Therapies at the South Texas Blood & Tissue Center, part of BioBridge Global, outlines some of the major barriers to wider adoption of cell and gene therapies: complexity, variability, and the lack of robust standards. Dr Marshall also highlights the…